APOA1 and systemic lupus erythematosus: Together, this study highlights key changes in cardiometabolic profiles across age in SLE, concluding that increasing HDL/ApoA1 levels, whilst maintaining low disease activity and minimizing exposure to steroids in SLE patients from a young age could improve cardiometabolic outcomes and mortality.